Kamada Pharmaceuticals reported revenue of $ 127.2 million in 2019 - up 11%

Kamada Pharmaceuticals reported revenue of $ 127.2 million in 2019 - up 11% on 2018. Gross profit in 2019 was $ 49.8 million, up 20% compared to 2018. Adjusted EBITDA in 2019 was $ 28.5 million, up Of 19% compared to 2018.
The company confirms its total revenue forecast for 2020 in the range of $ 132 million to $ 137 million.
 Revenue for the fourth quarter was $ 32.1 million. Gross profit in the fourth quarter was $ 12.1 million. Fourth-quarter adjusted EBITDA was $ 6.8 million. Comparing the fourth quarter results to the same period last year, it is important to submit that the fourth quarter 2018 financial results were significantly higher as a result of accelerated deliveries delayed in the third quarter of 2018 due to the workers' strike that was then in the company's manufacturing plant.
 "We are very pleased with our business performance during 2019," said Amir London, CEO of Kamada. "Our cash, cash equivalents and short-term investments stood at $ 73.9 million as of December 31, 2019, an increase of $ 23.3 million compared to the end of 2018. In addition , The recently funded $ 25 million private placement fund will support the continued implementation of our business development strategy, which focuses on identifying new product opportunities for our manufacturing plant and locating complementary products for licensing and purchasing.
 "During the fourth quarter of 2019, we signed two important deals that will contribute to our future growth. First, we signed an agreement with Albotech for marketing and distribution of six biosimilar products in Israel, subject to Israeli Health Regulatory Approvals; the first product is expected to be launched in Israel in 2022. Second, we have signed a binding principles document for a 12-year manufacturing and supply agreement with an unpublished partner for the FDA-approved commercial immunoglobulin product. We intend to sign this agreement during 2020 and we expect to begin commercial production of the product by early 2023. Donate about $ 8 million to $ 10 million in income Our annual, estimated gross profit is similar to the average gross profit of our industrial product sector, ”London said.